Qualigen Therapeutics (QLGN) 10-K 21 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 16, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	RITTER PHARMACEUTICALS INC
Entity Central Index Key	1,460,702
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 20,100,000
Entity Common Stock, Shares Outstanding		8,584,661
Trading Symbol	RTTR
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 15,819,566	$ 2,747,248
Prepaid expenses	189,136	57,115
Total current assets	16,008,702	2,804,363
Other assets	$ 10,326	10,331
Deferred offering costs		143,454
Property and equipment, net	$ 20,688	5,172
Total Assets	16,039,716	2,963,320
Current liabilities
Accounts payable	739,357	1,083,597
Accrued expenses	614,141	168,635
Other liabilities	1,223	2,518
Total current liabilities	$ 1,354,721	1,254,750
Preferred stock subject to redemption, $0.001 par value; 0 shares authorized, issued and outstanding as of December 31, 2015; 16,378,646 shares authorized, 13,399,668 shares issued and outstanding as of December 31, 2014		16,203,612
Stockholders’ equity (deficit)
Preferred stock, $0.001 par value; 5,000,000 and 8,887,500 shares authorized as of December 31, 2015 and December 31, 2014, respectively; 0 shares and 8,887,500 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively		8,888
Common stock, $0.001 par value; 25,000,000 and 50,000,000 shares authorized as of December 31, 2015 and December 31, 2014, respectively; 8,582,004 and 465,384 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 8,582	465
Additional paid-in capital	41,759,355	3,399,924
Accumulated deficit	(27,082,942)	(17,904,319)
Total stockholders’ equity (deficit)	14,684,995	(14,495,042)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 16,039,716	$ 2,963,320

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock subject to redemption, par value	$ 0.001	$ 0.001
Preferred stock subject to redemption, shares authorized	0	16,378,646
Preferred stock subject to redemption, shares issued	0	13,399,668
Preferred stock subject to redemption, shares outstanding	0	13,399,668
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	8,887,500
Preferred stock, shares issued	0	8,887,500
Preferred stock, shares outstanding	0	8,887,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	50,000,000
Common stock, shares issued	8,582,004	465,384
Common stock, shares outstanding	8,582,004	465,384

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating costs and expenses
Research and development	$ 2,260,297	$ 113,931
Patent costs	243,463	197,731
General and administrative	6,404,643	1,969,960
Total operating costs and expenses	8,908,403	2,281,622
Operating loss	(8,908,403)	(2,281,622)
Other income (expense)
Interest income	$ 40,876	525
Interest expense		(213,516)
Other income	$ 79,756	21,148
Other income (expense), net	120,632	(191,843)
Net loss	(8,787,771)	(2,473,465)
Cumulative preferred stock dividends	(327,569)	(589,462)
Accretion of discount of Series C preferred stock	(63,283)	(8,580)
Net loss attributable to common stockholders	$ (9,178,623)	$ (3,071,507)
Net loss attributable to common stockholders per share, basic and diluted	$ (3.11)	$ (6.79)
Weighted average shares outstanding, basic and diluted	2,946,792	452,509

Statements of Changes in Securi

Statements of Changes in Securities Subject to Redemption and Stockholders’ Equity (Deficit) - USD ($)	Preferred Stock Subject to Redemption [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 12,413,876	$ 8,888	$ 451	$ 2,059,347	$ (14,832,812)	$ (12,764,126)
Balance, shares at Dec. 31, 2013	10,408,652	8,887,500	451,398
Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock	$ 660,635			136,733		136,733
Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock, shares	621,788
Issuance of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767	$ 2,531,059			482,068		482,068
Issuance of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767, shares	2,369,228
Exercise of options on common stock			$ 14	14,386		14,400
Exercise of options on common stock, shraes			13,986
Stock-based compensation				707,390		707,390
Cumulative dividends on Series B preferred stock	$ 589,462				(589,462)	(589,462)
Accretion of discount on Series C preferred stock	8,580				(8,580)	(8,580)
Net loss					(2,473,465)	(2,473,465)
Balance at Dec. 31, 2014	$ 16,203,612	$ 8,888	$ 465	3,399,924	(17,904,319)	$ (14,495,042)
Balance, shares at Dec. 31, 2014	13,399,668	8,887,500	465,384
Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock
Exercise of options on common stock			$ 5	5,252		$ 5,257
Exercise of options on common stock, shraes			5,104
Stock-based compensation				2,894,509		2,894,509
Cumulative dividends on Series B preferred stock	$ 327,569				(327,569)	(327,569)
Accretion of discount on Series C preferred stock	$ 63,283				(63,283)	$ (63,283)
Exercise of prepaid forward sale of Series B preferred stock
Exercise of prepaid forward sale of Series B preferred stock, shares	1,469,994
Conversion of all outstanding preferred stock to common stock		$ (8,888)	$ 1,243	7,645
Conversion of all outstanding preferred stock to common stock, shares		(8,887,500)	1,243,002
Conversion of all outstanding preferred stock subject to redemption to common stock	$ (16,594,464)		$ 2,080	16,592,384		$ 16,594,464
Conversion of all outstanding preferred stock subject to redemption to common stock, shares	(14,869,662)		2,079,650
Common stock subject to repurchase				(180)		(180)
Issuance of common stock upon closing of initial public offering			$ 4,000	19,996,000		20,000,000
Issuance of common stock upon closing of initial public offering, shares			4,000,000
Issuance of common stock upon closing of common stock purchase agreement			$ 500	999,500		1,000,000
Issuance of common stock upon closing of common stock purchase agreement, shares			500,000
Commissions and offering costs of initial public offering				(2,551,390)		$ (2,551,390)
Issuance of common stock for commitment fee			$ 189	(189)
Issuance of common stock for commitment fee, shares			188,864
Issuance of common stock to supplier			$ 100	415,900		$ 416,000
Issuance of common stock to supplier, shares			100,000
Net loss					(8,787,771)	(8,787,771)
Balance at Dec. 31, 2015			$ 8,582	$ 41,759,355	$ (27,082,942)	$ 14,684,995
Balance, shares at Dec. 31, 2015			8,582,004

Statements of Changes in Secur6

Statements of Changes in Securities Subject to Redemption and Stockholders’ Equity (Deficit) (Parenthetical)	12 Months Ended
	Dec. 31, 2015USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of preferred stock subject to redemption and warrants to purchase common stock, offering cost	$ 68,767

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (8,787,771)	$ (2,473,465)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,939	3,479
Stock-based compensation	2,894,509	$ 707,390
Gain on disposal of equipment	(456)
Issuance of shares of common stock to supplier	$ 416,000
Accretion of debt discount		$ 10,192
Non-cash interest on conversion of debt		184,445
Changes in fair value of put embedded in convertible debt		(21,148)
Changes in operating assets and liabilities:
Prepaid expenses	$ (132,021)	19,521
Other assets		5,028
Accounts payable	$ (344,240)	249,101
Accrued expenses	231,950	160,071
Other liabilities	(1,475)	(1,999)
Net cash used in operating activities	(5,721,565)	(1,157,385)
Cash flows from investing activities
Purchases of property and equipment	(16,999)	(1,166)
Net cash used in investing activities	(16,999)	$ (1,166)
Cash flows from financing activities
Commissions and issuance costs of initial public offering	(2,194,375)
Proceeds from issuance of shares upon closing of initial public offering	20,000,000
Proceeds from the issuance of shares from common stock purchase agreement	1,000,000
Proceeds from exercise of options on common stock	$ 5,257	$ 14,400
Deferred offering costs		(143,454)
Proceeds of borrowing under notes payable		605,000
Repayment of borrowing under note payable		(31,500)
Net proceeds from issuance of preferred stock subject to redemption and warrants to purchase common stock		3,013,127
Net cash provided by financing activities	$ 18,810,882	3,457,573
Net increase in cash and cash equivalents	13,072,318	2,299,022
Cash and cash equivalents at beginning of year	2,747,248	448,226
Cash and cash equivalents at end of year	$ 15,819,566	$ 2,747,248
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of noncash financing activities
Accrual of commissions and issuance costs of the initial public offering	$ 213,561
Deferred offering costs reclassified to additional paid-in capital	665,603
Conversion of all outstanding preferred stock into common stock	8,888
Conversion of all outstanding preferred stock subject to redemption into common stock	16,594,464
Common stock subject to repurchase	180
Cumulative preferred stock dividends	327,569	$ 589,462
Accretion of discount on Series C preferred stock	63,283	$ 8,580
Common stock issued as commitment fee for stock purchase agreement	$ 400,392
Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock		$ 612,923

Organization and Principal Acti

Organization and Principal Activities	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Principal Activities	NOTE 1 — ORGANIZATION AND PRINCIPAL ACTIVITIES Ritter Pharmaceuticals, Inc. (“Ritter” or the “Company”) is a Delaware corporation headquartered in Los Angeles, California. The Company was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC, and converted into a Delaware corporation on September 16, 2008. Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics. The Company’s lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. There currently is no drug approved by the Food and Drug Administration (“FDA”) for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. The Company currently operates in one business segment focusing on the development and commercialization of RP-G28. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer. The Company does not currently operate any separate lines of business or separate business entities. Initial Public Offering On June 24, 2015, the Company’s registration statement on Form S-1 (File No. 333-202924) relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). The shares began trading on the NASDAQ Capital Market on June 24, 2015. The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial public offering price of $5.00 per share. The Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering. In addition, the Company incurred expenses of approximately $1 million in connection with the offering. Thus, the net offering proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, were approximately $17.4 million. Capitalization In connection with the Company’s initial public offering in June 2015, the Company effected a 1–for-7.15 reverse split of its common stock. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in these financial statements and notes to financial statements have been adjusted to reflect the reverse split on a retroactive basis.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 2 — BASIS OF PRESENTATION The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. Going Concern and Liquidity The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue and has not achieved profitable operations. The Company had net losses of approximately $8.8 million and $2.5 million for the years ended December 31, 2015 and 2014, respectively, and had net cash used in operating activities of approximately $5.7 million and $1.2 million, for the years ended December 31, 2015 and 2014, respectively. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and pre-clinical testing, and commercialization of the Company’s products will require significant financing. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Since inception, the operations of the Company have been funded through the sale of common shares, preferred shares and convertible debt. Management cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. If the Company is not able to raise additional capital when required or on acceptable terms, the Company may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seeks collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others; the valuation allowance of deferred tax assets resulting from net operating losses and the valuation of options on the Company’s common stock. Cash and Cash Equivalents Cash consists of amounts held in a financial institution and consists of immediately available fund balances. The funds were maintained at a stable financial institution, generally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date. Deferred Offering Costs Deferred offering costs as of December 31, 2014 primarily consist of direct, incremental banking, legal and accounting fees related to the public offering of the Company’s common stock, and are classified within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015. Property and Equipment Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method (see Note 4). Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Maintenance and repairs are charged to expense as incurred while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. Impairment of Long-Lived Assets The Company periodically assesses the impairment of long lived assets in accordance with Accounting Standards Codification (“ASC”) Topic 360, Property Plant and Equipment. Accrued Expenses The Company incurs periodic expenses such as research and development, salaries, and professional fees. An accrual is necessary when expenses have been incurred by the Company prior to them being paid. When a vendor’s invoice is not received, the Company is required to estimate its accrued expense. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise been notified of the actual cost. The majority of the Company’s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The Company estimates accrued expenses at each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC Topic 730, Research and Development Patent Costs The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred. Should the Company experience a legal cost to defend a patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed. Stock-based Compensation Stock-based compensation cost for stock awards issued to employees, members of the Company’s board of directors and non-employees, is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Stock-based compensation is recognized only for those awards that are ultimately expected to vest. Common stock, stock options or warrants issued to non-employees, including consultants and members of the Company’s Scientific Advisory Board as consideration for goods or services received by the Company, are accounted for based on the fair value of the equity instruments issued unless the fair value consideration received can be more reliably measured. The fair value of stock options is determined using the Black-Scholes option-pricing model. The fair value of any options issued to non-employees is recorded as expense over the vesting period. See Note 9 for further information. Fair Value Measurements The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: InpInputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. As of December 31, 2015 and 2014, the carrying amounts of cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses are generally considered to be representative of their fair value because of the short term nature of these instruments. No transfers between levels have occurred during the periods presented. Accounting for Income Taxes Deferred tax assets and liabilities are recognized for the expected future consequences of events that have been reflected in the financial statements. Deferred tax assets and liabilities are determined based on the differences between the book and tax basis of assets and liabilities and operating loss carryforwards, using tax rates expected to be in effect for the years in which the differences are expected to reverse. Such differences arise primarily from stock-based compensation and net operating loss carryforwards. The Company records a valuation allowance to reduce deferred income tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. Prior to September 15, 2008, the Company was a limited liability company and the Company’s tax losses and credits generally flowed directly to the members. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under the 2015 Equity Incentive Plan (described in Note 9) and warrants on the Company’s common stock (described in Note 8) are not considered in the computation of diluted net loss per share because they would be anti-dilutive. All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company’s common stock effected in June 2015. Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on investments are reported, net of their related tax effect, to arrive at a comprehensive loss. For the years ended December 31, 2015 and 2014, comprehensive loss was equal to the net loss. Recent Accounting Pronouncements On November 20, 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40) — Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Other accounting standards updates effective after December 31, 2015, are not expected to have a material effect on the Company’s financial position, annual results of operations and/or cash flows.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment consists of the following: Useful Life (Years) December 31, 2015 December 31, 2014 Furniture and fixtures 7 $ 15,840 $ 4,270 Computer equipment 5 9,696 5,487 25,536 9,757 Less: Accumulated depreciation and amortization (4,848 ) (4,585 ) Property and equipment, net $ 20,688 $ 5,172 Depreciation expense of approximately $1,900 and $3,500 was recognized for the years ended December 31, 2015 and 2014, respectively, and is classified in general and administrative expense in the accompanying Statements of Operations.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5 — CONVERTIBLE NOTES PAYABLE In 2014, the Company issued a combination of convertible notes payable and a note payable for a total principal balance of $605,000 (the “2014 Notes”) to two investors and converted all of these outstanding notes, plus accrued interest, into Series C preferred stock and warrants to purchase the Company’s common stock. These notes were convertible upon a qualified equity financing, pursuant to which the Company sold, with the principal purpose of raising capital, a new class of preferred stock with an aggregate sales price of not less than $3,000,000, including the principal and accrued but unpaid interest of any notes which are converted into the preferred securities (“Qualified Equity Financing”), or upon a change of control. The convertible notes payables with a principal balance of $535,000 settle by providing the holder with a variable number of the Company’s shares with an aggregate fair value determined by reference to the debt principal outstanding. Because the value that the holder receives at settlement does not vary with the value of the Company’s equity shares, the settlement provision is not considered a conversion option for financial accounting purposes. Rather, these notes are recognized as share-settled debt at amortized cost. Details of the 2014 Notes are as follows: (a) In May and September 2014, the Company issued a total of $455,000 of subordinated convertible promissory notes. These notes have a term of 12 months and bear interest at a rate of 8% per annum until paid in full. These notes are convertible upon a Qualified Equity Financing or upon a change of control at a price per share equal to seventy-five percent (75%) of the price per share paid by the investors (other than the 2014 Note holders) participating in the Qualified Equity Financing. The Company evaluated the change of control put embedded in these notes, which provides for cash settlement of these notes at two (2) times the principal amount upon a change of control, in accordance with ASC 815-15-25. The embedded change of control put is not clearly and closely related to the debt host instrument and therefore has been separately measured at fair value. The proceeds received upon issuing these notes was first allocated to the fair value of the embedded put with the remainder to the debt host instrument, resulting in a discount of approximately $21,000 to the face amount of the notes. The discount is amortized to interest expense over the term of the debt. The Company amortized approximately $10,000 to interest expense in the year ended December 31, 2014. Additionally, the Company recognized a gain of approximately $21,000 in the year ended December 31, 2014 due to the reduction in fair value of the put resulting from the decreased probability of a change in control occurring as the notes approached maturity and ultimate conversion. (b) In October 2014, the Company issued an $80,000 subordinated convertible promissory note. This note has a term of 12 months and bear interest at a rate of 8% per annum until paid in full. The terms of this note provided an automatic conversion upon a Qualified Equity Financing at a price per share equal to seventy-five percent (75%) of the price per share paid by the investors (other than the 2014 Note holders) participating in the Qualified Equity Financing. (c) In addition, the Company issued a $70,000 principal amount unsecured promissory note on October 9, 2014. This note bears interest at a rate of 5% per annum until paid in full. All principal and accrued interest under this note must be paid upon demand of the holder at any time after one year of the date of the note. As described in Note 7, all of the Company’s outstanding debt was converted or exchanged for Series C preferred stock and warrants to purchase common stock in December 2014.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 6 — COMMITMENTS AND CONTINGENCIES Master Services Agreement On December 30, 2015, we entered into a Master Service Agreement with Covance, Inc. (“Covance”), with an effective date of December 29, 2015. Pursuant to the terms of the Master Service Agreement, Covance (or one or more of its affiliates) will provide Phase 1, 2, 3, and 4 clinical services for a clinical study or studies to us, and, at our request, assist us with the design of such studies, in accordance with the terms of separate individual project agreements to be entered into by the parties. The term of the agreement is for three years and will renew automatically for successive one year periods unless Covance is no longer providing services under the agreement or either party has terminated the agreement upon written notice. We may terminate the Master Service Agreement or any individual project agreement entered into under the Master Service Agreement prior to the applicable study’s completion at any time for any reason upon 30 days written notice to Covance, except when the reason for termination is the safety of subjects, in which case it may be terminated immediately. Covance may not terminate any individual project agreement without cause, except when the reason for the termination is the safety of subjects, in which case it may be terminated immediately. In the event of a termination of the Master Service Agreement, Covance will be entitled to full payment for (i) work performed on the applicable project upon through the date work on such project is concluded and (ii) reimbursement for all non-cancellable and non-refundable expenses and financial obligations which Covance (or an affiliate) has incurred or undertaken on our behalf. Clinical Supply and Cooperation Agreement with Ricerche Sperimentali Montale (“Ricerche”) and Inalco SpA (“Inalco”) Effective July 24, 2015, we entered into an amended Clinical Supply and Cooperation Agreement (the “Amended Supply Agreement”) with Ricerche and Inalco (collectively, “RSM”). The Amended Supply Agreement amends certain terms of the Clinical Supply and Cooperation Agreement, dated December 16, 2009, amended on September 25, 2010 (the “Existing Supply Agreement”). Under the Existing Supply Agreement, RSM granted us an exclusive worldwide option in a specified field and territory to assignment of all right, title and interest to a purified Galacto-oligosaccharides product (“Improved GOS”), the composition of matter of the Improved GOS and any information relating to the Improved GOS, including certain specified technical information and other intellectual property rights (the “Improved GOS IP”). Pursuant to the amended terms, we could exercise the option by paying RSM $800,000 within ten days after the effective date of the Amended Supply Agreement. We exercised this option on July 30, 2015 and RSM transferred the Improved GOS IP to us. Under the terms of the Existing Supply Agreement, if a further option payment of $1 million due in the future is not made, we may be required to return the Improved GOS IP to RSM. The Amended Supply Agreement also provides that we must pay RSM $400,000 within 10 days following FDA approval of a new drug application for the first product owned or controlled by us using Improved GOS as its active pharmaceutical ingredient. In addition, we agreed to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo as under the Existing Supply Agreement. In consideration for RSM entering into the Amended Supply Agreement, we issued 100,000 shares of our common stock, par value $0.001 per share (the “RSM Shares”), to RSM on November 30, 2015. Fair value of these shares totaling $416,000 was recognized in stockholders’ equity in the balance sheet as of December 31, 2015. The stock purchase agreement includes a lock-up agreement by RSM in our favor pursuant to which RSM will not be able to sell the RSM Shares for a period ending on the earlier of (i) the public release by us of the final results of our Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of our Form 10-Q with the Securities and Exchange Commission for the fiscal quarter in which we receives the results of our Phase 2b/3 clinical trial of RP-G28. Lease Agreement We lease office space for our headquarters in California. Until September 30, 2015, we leased office and storage space pursuant to a two-year agreement which called for a minimum monthly rent of approximately $5,000 and an annual increase of 3%. On July 9, 2015, we entered into a lease with Century Park, a California limited partnership, pursuant to which we are leasing approximately 2,780 square feet of office space in Los Angeles, California for our headquarters. The lease provides for a term of sixty-one (61) months, commencing on October 1, 2015. We paid no rent for the first month of the term and will pay base rent of $9,174 per month for months 2 through 13 of the term, with increasing base rent for each twelve month period thereafter under the term of the lease to a maximum of $10,325 per month for months 50 through 61. The base rent payments do not include our proportionate share of any operating expenses, including real estate taxes. We have the option to extend the term of the lease for one five-year term, provided that the rent would be subject to market adjustment at the beginning of the renewal term. We will recognize rent expense on a straight-line basis over the lease term. Rent expense, recognized on a straight-line basis, was approximately $74,000 and $60,000 for the years ended December 31, 2015 and 2014, respectively, and is recorded in general and administrative expenses in the accompanying statements of operations. The following table summarized our lease obligations at December 31, 2015: LEASE COMMITMENTS Years ended December 31, Operating Lease 2016 $ 110,638 2017 113,958 2018 117,376 2019 120,898 2020 103,254 Total minimum lease payments $ 566,124 Employment Agreements Michael D. Step On December 2, 2014, Michael D. Step accepted an offer letter from us setting forth the terms of his employment as Chief Executive Officer. The offer letter provides that Mr. Step is entitled to an annual base salary of $360,000 and a total of three grants of options to purchase our common stock. The first two options entitle Mr. Step to purchase 646,537 and 73,377 of our shares, respectively, for an exercise price of $5.86 per share. Each of these options was immediately exercisable in full as of the date of the grant, with 44/48 ths th The third option became exercisable upon the closing of our initial public offering on June 29, 2015. The option is for a total of 163,799 shares of our common stock, which, together with the shares subject to the first option, represent 7.5% of the shares of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis, after giving effect to the number of shares subject to the third option. Seventy-five percent of the shares subject to the third option are subject to a right of repurchase by us upon termination of Mr. Step’s employment for any reason. This right of repurchase lapses with respect to 1/36 th Additionally, under the terms of his Executive Severance and Change in Control Agreement, also effective on December 2, 2014, Mr. Step is entitled to receive certain payments in the event his employment is terminated under certain scenarios. Andrew Ritter and Ira Ritter On September 25, 2013, our board of directors approved the Executive Compensation Plan (the “Compensation Plan”) setting forth certain compensation to be paid to Andrew Ritter, our current President and former Chief Executive Officer, and Ira Ritter, our current Chief Strategic Officer (“CSO”), for their respective contributions to our company. Effective June 29, 2015, in connection with our initial public offering, Andrew Ritter and Ira Ritter accepted offer letters from us setting forth the terms of their employment as President and CSO, respectively, of the Company. The offer letters superseded the Compensation Plan. Their respective offer letters provide that that Andrew Ritter is entitled to an annual base salary of $310,000 and Ira Ritter is entitled to an annual base salary of $295,000. In accordance with his offer letter, Andrew Ritter also became entitled to receive up to $180,000 payable over a three year period for tuition reimbursement. As of December 31, 2015, we paid an aggregate of $105,000 and have an accrual of $75,000 in tuition reimbursement for Andrew Ritter and recognized such amount in general and administrative expenses in the accompanying statements of operations for the year ended December 31, 2015. Additionally, under the terms of their Executive Severance and Change in Control Agreements, also effective on June 29, 2015, each of Andrew Ritter and Ira Ritter is entitled to receive certain payments in the event their employment is terminated under certain scenarios. Pursuant to their respective offer letters, Andrew Ritter and Ira Ritter each have the opportunity to earn an annual bonus based upon a percentage of their base salary and the achievement of specific performance as determined by the Company. The initial target bonus opportunities are 40% and 35% of the base salary for Andrew Ritter and Ira Ritter, respectively. The board of directors determined that the specific performance requirements were met for fiscal year 2015 and accordingly, Andrew Ritter received 40% of his base salary, or $124,000 and Ira Ritter received 35% of his base salary, or $103,250. These bonus payments are recognized in general and administrative expense in the accompanying statements of operations for the year ended December 31, 2015. Pursuant to the Compensation Plan, as in effect prior to entering into their offer letters, Andrew Ritter and Ira Ritter had bonus opportunities to, upon the satisfaction of the events described below, each potentially receive the following cash payments and each potentially receive the following options to purchase up to 48,951 shares of our common stock (the “Executive Options”) pursuant to the 2008 Stock Plan: ● FDA Meeting Bonus Opportunities ● Clinical Trial Funding Commitment Bonus Opportunities ● Fundraising Bonus Opportunities ● License Event Bonus Opportunities o A graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined in the Compensation Plan) up to $5,000,000; (ii) 4% of the Initial Period License Payment in excess of $5,000,000 up to $10,000,000; and (iii) 3% of the Initial Period License Payment in excess of $10,000,000. In addition, upon our receipt of an Initial Period License Payment of more than $2,000,000, 35% of 45,454 shares of their Executive Options will vest and become exercisable, with the balance of the 45,454 shares vesting in 36 monthly installments beginning on the last day of the following month. o A cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined in the Compensation Plan); provided, however that no such bonus may be paid at any time the Company has less than $1,000,000 in available cash. In addition, upon our receipt of an Annual Excess Milestone Payment, 35% of 6,993 shares of their Executive Options will vest and become exercisable, with the balance of the 6,993 shares vesting in 36 monthly installments beginning on the last day of the following month. As of December 31, 2015, 27,972 of the maximum 48,951 Executive Options potentially issuable to each executive had been issued to each executive subject to the vesting conditions described above. Legal The Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) and Preferred Stock Subject to Redemption	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity (Deficit) and Preferred Stock Subject to Redemption	NOTE 7 — STOCKHOLDERS’ EQUITY (DEFICIT) AND PREFERRED STOCK SUBJECT TO REDEMPTION Common Stock As of December 31, 2014, the Company was authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share. Effective June 17, 2015, the Company effected a 1-for-7.15 reverse stock split and all common share amounts and per share amounts reflected in these financial statements and notes to financial statements have been adjusted to reflect that reverse stock split. The Company amended and restated its Certificate of Incorporation on June 29, 2015 (“the Amended Certificate”) and reduced the authorized shares of the Company’s common stock to 25,000,000 with a par value of $0.001 per share. Initial Public Offering On June 29, 2015, the Company closed its initial public offering, selling 4,000,000 shares of the Company’s common stock at an initial public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million. The Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering, and approximately $1 million of other expenses in connection with the offering. The underwriters paid an aggregate purchase price of $100 for warrants to purchase 160,000 shares of the Company’s common stock, representing 4.0% of the initial public offering shares, at an exercise price of $6.25 per share, which equaled 125.0% of the initial public offering price. The warrants are exercisable on June 29, 2016 and expire on June 29, 2020. Effective prior to the closing of the initial public offering, the Company converted all of its outstanding shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred into an aggregate of 3,322,652 shares of the Company’s common stock. Common Stock Purchase Agreement On December 18, 2015, the Company entered into a common stock purchase agreement (the “Purchase Agreement”), with Aspire Capital Fund, LLC, an Illinois limited liability company, (“Aspire Capital”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of the Company’s shares of common stock over the approximately 30-month term of the Purchase Agreement. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 188,864 shares of the Company’s common stock as a commitment fee (the “Commitment Shares”). The fair value of the Commitment Shares were capitalized and recorded as a reduction of additional paid-in capital. Upon execution of the Purchase Agreement, the Company agreed to sell to Aspire Capital 500,000 shares of common stock, or the Initial Purchase Shares, at $2.00 per share for proceeds of $1.0 million. Preferred Stock The Company’s Board of Directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of the authorized shares of preferred stock in series and to establish the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions thereon. Pursuant to the Amended Certificate, as of June 29, 2015, the Company was authorized to issue 5,000,000 shares of preferred stock, $0.001 par value per share. Prior to the Amended Certificate and as of December 31, 2014, the Company was authorized to issue 7,200,000 shares, 1,687,500 shares, 4,220,464 shares, 7,658,182 shares, and 4,500,000 shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock, respectively, with a par value of $0.001 per share. Upon the closing of the Company’s initial public offering, all outstanding shares of convertible preferred stock and preferred stock subject to redemption were converted into an aggregate of 3,322,652 shares of common stock. The following provides material terms and certain historical information regarding the Series A-1, Series A-2, Series A-3, Series B and Series C Preferred Stock prior to their conversion to common stock: Redemption. Dividends. Liquidations Series C Financing In December 2014, the Company issued an aggregate of 2,369,228 shares of Series C preferred stock and warrants to purchase an aggregate of 331,358 shares of the Company’s common stock (the “Warrants”), for aggregate gross proceeds of $3,081,893 (the “Series C Financing”). All of these shares of Series C preferred stock were converted into 331,358 shares of the Company’s common stock prior to the closing of the initial public offering. Each Warrant has a term of seven years and provides for the holder to purchase one share of the Company’s common stock at a purchase price of $9.30 per share of common stock. The Warrants are indexed to the Company’s own stock and classified within stockholders’ equity pursuant to ASC 815-40. The gross proceeds were allocated to the Series C preferred stock and Warrants on a relative fair value basis, resulting in a per share value of $7.83 for the Series C preferred stock. The allocation of proceeds to the Warrants creates a discount of $1.47 in the initial carrying per share value of the Series C preferred stock, which was recognized as accretion, similar to preferred stock dividends, over the five-year period prior to optional redemption by the holders. In connection with the Series C Financing, all of the 2014 Notes were converted into shares of Series C preferred stock and Warrants as follows: ● $535,000 unpaid principal plus accrued interest of $18,342 on convertible notes converted into 567,529 shares of Series C preferred stock, which was later converted into 79,374 shares of the Company’s common stock, and 79,374 Warrants. ● $70,000 unpaid principal plus accrued interest of $537 on a note payable extinguished and converted into 54,259 shares of Series C preferred stock, which was later converted into 7,589 shares of the Company’s common stock and 7,589 Warrants. Notes with an unpaid principal balance of $535,000 were converted into shares of Series C preferred stock and warrants to purchase shares of common stock at 75% of the price paid by other purchasers of the Series C Financing. The Company recognized additional interest expense of $184,445 upon conversion, calculated as the fair value of incremental shares and warrants received by the holders compared to converting the outstanding debt and accrued interest at 100% of the price paid by purchasers of the Series C Financing. The note with an unpaid principal balance of $70,000 was exchanged for shares of Series C preferred stock and warrants to purchase shares of common stock at a price per share equal to the price per share paid by purchasers of the Series C Financing. As such, there was no gain recognized or loss incurred upon extinguishment of the note in 2014. Prepaid Forward Sale of Preferred Stock Research and Development Agreement & License On November 30, 2010, the Company concurrently entered into a Research and Development Agreement & License (“R&D Agreement”) and a Put and Call Option Agreement (“Option Agreement”) with two commonly controlled entities, Kolu Pohaku Technologies, LLC (“KPT”) and Kolu Pohaku Management, LLC (“KPM”). The R&D Agreement was subsequently amended on July 6, 2011, September 30, 2011, February 6, 2012 and November 4, 2013 to increase the funding received by the Company. The R&D Agreement between the Company and KPM and KPT, a Qualified High Technology Business within the meaning of Hawaii Revised Statutes, called for KPT to make a series of payments to the Company totaling $1,750,000 in exchange for the Company performing research and development activities in Hawaii for the benefit of KPT (referred to herein as the KP Research). The KP Research consisted of the initial phase of research, including the conduct of Phase II clinical trials in Hawaii for RP-G28. Pursuant to the terms of the R&D Agreement, the Company maintained ownership of the results of the Company’s ongoing research related to RP-G28, but KPT maintained ownership of the results of the KP Research. Inventions, developments and improvements arising out of the KP Research were owned by KPT. Under the terms of the R&D Agreement, the Company would bear any costs involved in obtaining patents for any inventions, developments or improvements resulting from the Research Project. In exchange for the irrevocable, perpetual, exclusive, worldwide right and license to the results of the KP Research, as they are generated under this R&D Agreement, the Company agreed to pay a quarterly royalty payment to KPT of $32,000 commencing March 31, 2015 and continuing through December 31, 2035 or until such time as the KPM put or call option (as described below) was exercised. On March 26, 2015, the Company exercised the KPM put option and issued 1,469,994 shares of Series B preferred stock to KPM, resulting in the full satisfaction of the Company’s obligation to make royalty payments to KPT. Option Agreement Pursuant to the terms of the KPM Option Agreement, the Company had the right to put 1,469,994 shares of the Company’s Series B Preferred Stock (“Series B”) to KPM and KPM had the option to call the same amount of shares of Series B from the Company at any time after December 31, 2014. The number of shares was determined by dividing the $1,750,000 of payments made by KPT to the Company under the R&D Agreement by the Series B preferred stock original issue price of $1.19. Exercise of the put or call option would result in full satisfaction of the Company’s obligation to make royalty payments to KPT under the R&D Agreement and KPT’s right, title and interest in the research conducted pursuant to the R&D Agreement would become the property of the Company. On March 26, 2015, the Company exercised its right to the KPM put option and issued 1,469,994 shares of Series B preferred stock to KPM. Pursuant to the terms of the KPM Option Agreement, this resulted in the full satisfaction of the Company’s obligation to make royalty payments to KPT under the R&D Agreement and also resulted in the termination of the R&D Agreement and all of KPT’s right, title and interest in and to the KP Research, which rights now belong to the Company. The R&D Agreement and the put or call option have been recognized on a combined basis, pursuant to ASC 815-10-15-9, as a fully prepaid forward sale contract on the Company’s Series B preferred stock. The fully prepaid forward sale contract is a hybrid instrument comprising (1) a debt host instrument and (2) an embedded forward sale contract, requiring the Company to issue 1,469,994 shares of the Company’s Series B for no further consideration. Payments received by the Company, totaling $1,750,000, are recognized as preferred stock subject to redemption in the balance sheet as of December 31, 2014. The Company converted these shares into an aggregate of 205,593 shares of the Company’s common stock upon the closing of the IPO.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 8 — WARRANTS As described in Note 7, in 2014, the Company issued seven-year warrants (the “Warrants”) to investors for the purchase of 418,321 shares of the Company’s common stock at an exercise price of $9.30 per share. Also described in Note 7, upon closing of the IPO, the underwriter paid an aggregate purchase price of $100 for the option to purchase an aggregate 160,000 shares of the Company’s common stock at an exercise price of $6.25 per share. The Company analyzed the Warrants in accordance with ASC Topic 815 to determine whether the Warrants meet the definition of a derivative and, if so, whether the Warrants meet the scope exception that provides for equity classification of derivative instruments issued or held by the reporting entity that are both (1) indexed to its own stock and (2) classified in stockholders’ equity. The Company concluded these Warrants should be classified as equity since they contain no provisions, which would require recognition as a liability. The following represents a summary of the warrants outstanding at December 31, 2015 and changes during the period then ended: Weighted Average Warrants Exercise Price Outstanding at December 31, 2014 418,323 $ 9.30 Granted 160,000 $ 6.25 Exercised/Expired/Forfeited — — Outstanding at December 31, 2015 578,323 $ 8.45 Exercisable at December 31, 2015 418,323 $ 9.30

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	NOTE 9 — STOCK-BASED COMPENSATION Terms of the Company’s share-based compensation are governed by the Company’s 2015 Equity Incentive Plan, 2009 Stock Plan and 2008 Stock Plan (collectively the “Plans”.) The Plans permit the Company to grant non-statutory stock options, incentive stock options and other equity awards to the Company’s employees, outside directors and consultants; however, incentive stock options may only be granted to the Company’s employees. Beginning June 29, 2015, no further awards may be granted under the 2009 Stock Plan or 2008 Stock Plan. As of December 31, 2015, the aggregate number of shares of common stock available for issuance under the 2015 Equity Incentive Plan is 172,448. However, to the extent awards under the 2008 Plan or 2009 Plan are forfeited or lapse unexercised or are settled in cash, the common stock subject to such awards will be available for future issuance under the 2015 Equity Incentive Plan. The exercise price for an option issued under the Plans is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year period. Options Issued to Directors and Employees as Compensation Pursuant to the terms of the Plans, from inception to December 31, 2014, the Company issued options to purchase an aggregate of 1,996,712 shares to its executive officers and employees of the Company and non-employee directors for their services on the Board and its committees. Of these, 82,107 options were expired or exercised and 1,914,605 options remain outstanding as of December 31, 2014. The exercise prices of these option grants, as determined by the Company’s Board of Directors, range from $0.79 to $13.23 per share, and a portion of these vest subject to certain performance conditions. In 2015, the Company granted an aggregate of 30,000 non-qualified 10-year term options to purchase the Company’s common stock to its Board of Directors and an aggregate of 41,957 options to purchase the Company’s common stock were automatically terminated due to certain performance conditions not being met. As of December 31, 2015, the Company has a total of 1,902,648 options issued to its executive officers, employees and non-employee directors outstanding. The exercise prices of the outstanding options, as determined by the Company’s Board of Directors, range from $0.79 to $13.23 per share, and a portion of these vest subject to certain performance conditions. The Company recognized stock-based compensation expense for these services within general and administrative expense in the accompanying statements of operations of approximately $2.9 million and $0.7 million for the years ended December 31, 2015 and 2014, respectively. As of December 31, 2015, there was approximately $2.1 million of total unrecognized compensation cost related to un-vested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.5 years. Options Issued to Nonemployees for Services Received The Company has issued options to purchase an aggregate of 106,573 shares of the Company’s common stock since inception to 2014 to nonemployee consultants under the Plans. Of these, 68,662 options were expired or exercised and 37,911 options remain outstanding as of December 31, 2014. In 2015, the Company granted an aggregate of 4,000 non-qualified 10-year term options to purchase the Company’s common stock to it nonemployee contractors. During 2015, 6,025 options were expired or exercised and 35,886 options remain outstanding as of December 31, 2015. The exercise prices of the outstanding options, as determined by the Company’s Board of Directors, range from $0.72 to $2.25 per share. These outstanding options, with the exception of an option to purchase 7,272 shares granted to a consultant, vest 25% upon the first anniversary of the vesting commencement date with the remaining options vesting monthly in equal amounts over 36 months. The Company recognized an expense for these services of approximately $1,300 and $13,000 for the years ended December 31, 2015 and 2014, respectively, within research and development expense in the accompanying statements of operations. Options Valuation The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation expense to non-employees determined at the date of grant. Stock-based compensation expense to non-employee consultants affects the Company’s general and administrative expenses and research and development expenses. The fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: Years ended December 31, 2015 2014 Expected dividend yield 0.00% 0.00% Expected stock-price volatility 51.45% - 67.08% 51.45% - 64.24% Risk-free interest rate 0.77% - 2.27% 0.88% - 3.04% Term of options 10 5 - 10 Stock price $1.70 - $5.86 $1.14 - $5.86 ● Expected dividend yield. ● Expected stock-price volatility. ● Risk-free interest rate. ● Expected term. In addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for the Company’s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for the Company’s stock-based compensation calculations on a prospective basis. Significant factors, assumptions and methodologies used in determining the estimated fair value of the Company’s common stock The Company is also required to estimate the fair value of the common stock underlying the Company’s stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. The Company’s Board of Directors, with the assistance of management, determined the fair value of the Company’s common stock on each grant date. Option grants are based on the estimated fair value of the Company’s common stock on the date of grant, which is determined by taking into account several factors, including the following: ● the prices at which the Company sold the Company’s convertible preferred stock and the rights, preferences, and privileges of the convertible preferred stock relative to those of the Company’s common stock, including the liquidation preferences of the convertible preferred stock; ● important developments in the Company’s operations; ● the Company’s actual operating results and financial performance; ● conditions in the Company’s industry and the economy in general; ● stock price performance of comparable public companies; ● the estimated likelihood of achieving a liquidity event, such as an IPO or an acquisition of the Company, given prevailing market conditions; and ● the illiquidity of the common stock underlying stock options. The table below presents the prices received from sales to third parties of the Company’s common stock and various classes of the Company’s preferred stock from inception to date: Year Share Class Price per Share 2005 Common Stock (a) $ 1.79 2006 Series A-2 Preferred Stock (a)(b) $ 0.40 2008 – 2009 Series A-3 Preferred Stock (b) $ 0.62 2010 – 2013 Series B Preferred Stock (b) $ 1.19 2014 Series C Preferred Stock (b) $ 1.30 (a) After giving effect to the Company’s conversion from an LLC to a corporation (b) Each share of preferred stock is convertible into shares of the Company’s common stock on a 7.15-for-1 basis, after giving effect to the Company’s reverse stock split, which was effected on June 17, 2015. For options issued from inception to 2013, in determining the estimated fair value of the Company’s common stock, the Company’s Board of Directors, with the assistance of management, used the market approach to estimate the enterprise value of the Company in accordance with the American Institute of Certified Public Accountants (“AICPA”) Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the “AICPA Guide”) for the three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010. The Market Approach is one of the three approaches (along with the Income Approach and Asset Approach) used to estimate enterprise and equity value. The market approach employs analysis using comparable companies in determining the value of the entity. Both public and private companies, if publicly available information exists, are considered in the market approach. Two information points commonly available — company valuation and transaction value — are used for their respective methodologies. There are a number of different methods within the Market Approach that may be used: the three main methods utilized are: the Guideline Pubic Companies Method; the Guideline Transactions Method; and the Backsolve Method. Given the early stage of the Company, the Backsolve Method was used to estimate the fair value of the Company’s securities. This method derives an implied market value of invested capital from a transaction involving a company’s own securities. The price of a company’s security that was involved in a recent arms-length transaction is used as a reference point in an allocation of value. The Company first raised additional capital through the sales of the Company’s LLC units. These units later converted into common shares and preferred shares upon the Company’s conversion to a corporation. Subsequent to the Company’s corporation conversion, the Company raised additional capital through the sales of the Company’s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred shares at the price of  $0.07, $0.40, $0.62, $1.19, and $1.30, respectively. The Company valued LLC units and common stock (after converting to a corporation) from inception through 2009 by reference to the Company’s sales of units and/or common stock & preferred stock over the period. Beginning in 2010, the Company valued the Company’s common stock using the Backsolve Method. The Backsolve Method requires considering the rights and preferences of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction in the Company’s own securities, considering the rights and preferences of each class of equity. However, management has decided that the liquidation preferences between the Company’s preferred shares and common shares are immaterial for a pre-revenue company. Per the AICPA Guide, the Backsolve Method is generally the most reliable indicator of value of early-stage enterprises with no product revenue or cash flow, if relevant and reliable transactions have occurred in the Company’s equity securities. This methodology is also prescribed by the AICPA when a valuation is conducted in close proximity to the date of a financing transaction, and when other methodologies are deemed less reliable. The stage of development of the Company’s compound was reflected in the Company’s selection of the term and volatility estimates used in the analysis. The estimate of the term considers the Company’s existing cash runway and the time to the next potential financing or liquidity event, while the volatility estimate reflects the relative riskiness of the Company’s equity securities (or asset base) relative to the general stock market. Management estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company’s preferred shares for one common share through the option-pricing method. The premise of this method is that the transaction implied a market price for a share which in turn implied values for the other classes of equity based on relative claims on equity value, such as liquidation preferences and conversion rights. The application of the backsolve method considering the Company’s capital structure yielded a total market value of invested capital of approximately $15.5 million, $14.4 million, and $8.9 million, of which approximately $819,000, $870,000, and $670,000 were allocated to the total value of common stock as of the Company’s three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010, respectively. On the three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010, after estimating the market value of invested capital, the Company allocated it to the various equity classes comprising the subject company’s capitalization table. This process ultimately results in creating a final estimate of value for the subject company’s underlying equity interests. While there are many different value allocation methods, these various methods can be grouped into three general categories as defined by the AICPA Guide, one of which is the Option-Pricing Method (“OPM”). The Company used the OPM to allocate market value of invested capital to the various equity classes and debt comprising the Company’s capitalization structure. The Company chose the OPM over other acceptable methods due to the complex capital structure, the uncertainty related to market conditions, and the lack of visibility on an imminent exit event. Under the OPM, each equity class is modeled as a call option with a distinct claim on the equity of the Company. The option’s exercise price is based on the Company’s total equity value available for each participating equity holder. The characteristics of each equity class determine the equity class’ claim on the total equity value. By constructing a series of options in which the exercise price is set at incremental levels of value, which correspond to the equity value necessary for each level of equity to participate, the Company determined the incremental option value of each series. When multiplied by the percentage of ownership of each equity class participating under that series, the result is the incremental value allocated to each class under that series. The OPM relies on the Black-Scholes option-pricing model to value the call options on the Company’s invested capital. The following inputs were applied in the Black-Scholes calculations of the OPM: Valuation Dates November 7, 2013 July 31, 2012 December 31, 2010 Risk-free rate 0.55 % 0.57 % 2.01 % Maturity (years) 3.00 4.00 5.00 Volatility 58.00 % 61.00 % 61.00 % Discounts ranging from 35.8% to 40% were applied for lack of control and lack of marketability for the common stock. The calculation resulted in a fair value for the common stock of $1.17, $1.19, and $1.03 per share as of the Company’s three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010, respectively. For options issued in 2014, given the Company’s distinct possible exit scenarios of an initial public offering, the Company used the probability weighted expected return method (PWERM) to estimate the fair value of the Company’s common equity. Under this method, an analysis of future values of a company is performed for several likely liquidity scenarios. The value of the common stock is determined for each scenario at the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. The present values of the common stock under each scenario are then weighted based on the probability of each scenario occurring to determine the value for the common stock. The Company’s management determined the probability weighting of potential liquidity events to be 45% for an initial public offering and 55% for other scenarios, which represents all other likely outcomes for the Company. Management estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company’s preferred shares for one common share through the use of OPM. The application of the backsolve method considering the Company’s capital structure yielded a total market value of invested capital of approximately $25.2 million, of which approximately $1.4 million was allocated to the total value of common stock as of the Company’s valuation date of October 31, 2014. Given the lack of marketability for the common stock, the Company applied a discount of 21.4% for using the average strike put option approach. This resulted in a probability weighted common share value, after adjustment, of $5.86 per share as of valuation date of October 31, 2014. Stock-based Compensation Summary Tables Information regarding the Company’s stock option grants to the Company’s employees and non-employees, along with the estimated fair value per share of the underlying common stock, for stock options granted since 2005 is summarized as follows: Grant Date Number of Common Shares Underlying Options Granted Exercise Price per Common Share Estimated Fair Value per Share of Common Stock Intrinsic Value Per Option 2005 58,321 $ 0.07 $ 1.79 $ 1.72 2009 60,559 $ 0.72 - $0.79 $ 4.43 $ 3.71 - $3.64 2011 33,846 $ 1.03 $ 1.00 $ 0.00 2012 60,019 $ 1.14 $ 1.14 $ 0.00 2013 100,000 $ 1.14 - $1.30 $ 1.14 $ 0.00 2014 1,626,740 $ 5.86 - $13.23 $ 5.86 $ 0.00 2015 34,000 $ 2.25 $ 2.25 $ 0.00 The following represents a summary of the options granted to employees and non-employees outstanding at December 31, 2015 and changes during the period then ended: Options Weighted Average Exercise Price Outstanding at December 31, 2014 1,952,516 $ 7.022 Granted 34,000 2.250 Exercised/Expired/Forfeited (47,982 ) (1.246 ) Outstanding at December 31, 2015 1,938,534 $ 7.081 Exercisable at December 31, 2015 697,832 $ 5.285 Expected to be vested 1,240,702 $ 8.091

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 10 — RELATED PARTY TRANSACTIONS A director of the Company is a managing director of Javelin Venture Partners GP, LLC, the general partner of Javelin Venture Partners GP, L.P., which held a significant investment in the Company’s Series A-1, Series A-2, Series A-3, Series B, and Series C preferred stock that was converted into common stock prior to the Company’s initial public offering. Two directors of the Company have acted as a managing director of Stonehenge Partners, LLC, which held significant investment in the Company’s Series A-1 preferred stock and also held investments in the Company’s Series A-2 and Series B preferred stock that was converted to common stock prior to the Company’s initial public offering. Prior to and during his employment with the Company, Mr. Ira Ritter served as CEO of Andela Group Inc, (“Andela”) a company he founded in 1987, which is involved in corporate management, strategic and financial consulting. During the year ended December 31, 2014, the Company incurred approximately $176,000 of expenses for services received from Andela, all of which were classified in general and administrative expenses in the statements of operations as Mr. Ritter was an employee of the Company at the time of the services. There were no services received from Andela during the year ended December 31, 2015. Other than disclosed, the Company has not entered into or been a participant in any transaction in which a related party had or will have a direct or indirect material interest.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 — INCOME TAXES As of December 31, 2015, the Company has net operating loss carryforwards of approximately $15.3 million available to reduce future taxable income, if any, for Federal and state income tax purposes. The U.S. federal and state net operating loss carryforwards will begin to expire in 2028. As of December 31, 2015, the Company has research and development credit carryforwards of approximately $488,000 available to reduce future taxable income, if any, for Federal and state income tax purposes. The Federal credit carryforwards begin to expire in 2028. California credits have no expiration date. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss and research tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2015. The Company has no income tax affect due to the recognition of a full valuation allowance on the expected tax benefits of future loss carry forwards based on uncertainty surrounding realization of such assets. A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: December 31, 2015 2014 Statutory U.S. federal rate 34.0 % 34.0 % State income tax, net of federal benefit 5.8 % 3.9 % Meals & entertainment (0.1 )% (0.3 )% Others 0.0 % (0.5 )% Forward sale of preferred stock 0.0 % (2.3 )% Non-cash interest on conversion 0.0 % (2.8 )% Valuation allowance (39.7 )% (32.0 )% Provision for income taxes 0.0 % 0.0 % The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: As of December 31, 2015 2014 Deferred tax assets: Net operating loss carry forwards $ 6,192,058 $ 3,675,012 Patent costs 410,913 318,652 Capitalized interest 85,568 85,568 Accrued vacation 27,852 10,237 Research and development credit 345,721 200,482 Stock-based compensation 1,480,266 383,381 Other 5,195 4,460 Gross deferred tax assets 8,547,573 4,677,792 Valuation allowance (8,547,573 ) (4,677,792 ) Net deferred tax assets $ — $ — The Company did not record any accruals for income tax accounting uncertainties for the years ended December 31, 2015 and 2014 . Authoritative guidance requires companies to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company did not accrue either interest or penalties from inception through December 31, 2015. The Company does not have any unrecognized tax benefits that will significantly decrease or increase within 12 months of December 31, 2015. The Company’s major tax jurisdictions are the United States and California. All of the Company’s tax years will remain open three and four years for examination by the Federal and state tax authorities, respectively, from the date of utilization of the net operating loss. The Company does not have any tax audits pending.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others; the valuation allowance of deferred tax assets resulting from net operating losses and the valuation of options on the Company’s common stock.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash consists of amounts held in a financial institution and consists of immediately available fund balances. The funds were maintained at a stable financial institution, generally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs as of December 31, 2014 primarily consist of direct, incremental banking, legal and accounting fees related to the public offering of the Company’s common stock, and are classified within long term assets. The deferred offering costs were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method (see Note 4). Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Maintenance and repairs are charged to expense as incurred while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company periodically assesses the impairment of long lived assets in accordance with Accounting Standards Codification (“ASC”) Topic 360, Property Plant and Equipment.
Accrued Expenses	Accrued Expenses The Company incurs periodic expenses such as research and development, salaries, and professional fees. An accrual is necessary when expenses have been incurred by the Company prior to them being paid. When a vendor’s invoice is not received, the Company is required to estimate its accrued expense. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise been notified of the actual cost. The majority of the Company’s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The Company estimates accrued expenses at each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary.
Research and Development	Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC Topic 730, Research and Development
Patent Costs	Patent Costs The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred. Should the Company experience a legal cost to defend a patent in the future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit of the patent. Costs related to an unsuccessful outcome would be expensed.
Stock-based Compensation	Stock-based Compensation Stock-based compensation cost for stock awards issued to employees, members of the Company’s board of directors and non-employees, is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Stock-based compensation is recognized only for those awards that are ultimately expected to vest. Common stock, stock options or warrants issued to non-employees, including consultants and members of the Company’s Scientific Advisory Board as consideration for goods or services received by the Company, are accounted for based on the fair value of the equity instruments issued unless the fair value consideration received can be more reliably measured. The fair value of stock options is determined using the Black-Scholes option-pricing model. The fair value of any options issued to non-employees is recorded as expense over the vesting period. See Note 9 for further information.
Fair Value Measurements	Fair Value Measurements The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: InpInputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. As of December 31, 2015 and 2014, the carrying amounts of cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses are generally considered to be representative of their fair value because of the short term nature of these instruments. No transfers between levels have occurred during the periods presented.
Accounting for Income Taxes	Accounting for Income Taxes Deferred tax assets and liabilities are recognized for the expected future consequences of events that have been reflected in the financial statements. Deferred tax assets and liabilities are determined based on the differences between the book and tax basis of assets and liabilities and operating loss carryforwards, using tax rates expected to be in effect for the years in which the differences are expected to reverse. Such differences arise primarily from stock-based compensation and net operating loss carryforwards. The Company records a valuation allowance to reduce deferred income tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. Prior to September 15, 2008, the Company was a limited liability company and the Company’s tax losses and credits generally flowed directly to the members.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under the 2015 Equity Incentive Plan (described in Note 9) and warrants on the Company’s common stock (described in Note 8) are not considered in the computation of diluted net loss per share because they would be anti-dilutive. All common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company’s common stock effected in June 2015.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on investments are reported, net of their related tax effect, to arrive at a comprehensive loss. For the years ended December 31, 2015 and 2014, comprehensive loss was equal to the net loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements On November 20, 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40) — Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Other accounting standards updates effective after December 31, 2015, are not expected to have a material effect on the Company’s financial position, annual results of operations and/or cash flows.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and equipment	Property and equipment consists of the following: Useful Life (Years) December 31, 2015 December 31, 2014 Furniture and fixtures 7 $ 15,840 $ 4,270 Computer equipment 5 9,696 5,487 25,536 9,757 Less: Accumulated depreciation and amortization (4,848 ) (4,585 ) Property and equipment, net $ 20,688 $ 5,172

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Summarized Operating Lease Obligations	The following table summarized our lease obligations at December 31, 2015: LEASE COMMITMENTS Years ended December 31, Operating Lease 2016 $ 110,638 2017 113,958 2018 117,376 2019 120,898 2020 103,254 Total minimum lease payments $ 566,124

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Activity	The following represents a summary of the warrants outstanding at December 31, 2015 and changes during the period then ended: Weighted Average Warrants Exercise Price Outstanding at December 31, 2014 418,323 $ 9.30 Granted 160,000 $ 6.25 Exercised/Expired/Forfeited — — Outstanding at December 31, 2015 578,323 $ 8.45 Exercisable at December 31, 2015 418,323 $ 9.30

Stock-Based compensation (Table

Stock-Based compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule Assumptions Used in Black-scholes Option-pricing Method	The fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: Years ended December 31, 2015 2014 Expected dividend yield 0.00% 0.00% Expected stock-price volatility 51.45% - 67.08% 51.45% - 64.24% Risk-free interest rate 0.77% - 2.27% 0.88% - 3.04% Term of options 10 5 - 10 Stock price $1.70 - $5.86 $1.14 - $5.86
Schedule of Price Received from Sales to Third Parties of Common stock	The table below presents the prices received from sales to third parties of the Company’s common stock and various classes of the Company’s preferred stock from inception to date: Year Share Class Price per Share 2005 Common Stock (a) $ 1.79 2006 Series A-2 Preferred Stock (a)(b) $ 0.40 2008 – 2009 Series A-3 Preferred Stock (b) $ 0.62 2010 – 2013 Series B Preferred Stock (b) $ 1.19 2014 Series C Preferred Stock (b) $ 1.30 (a) After giving effect to the Company’s conversion from an LLC to a corporation (b) Each share of preferred stock is convertible into shares of the Company’s common stock on a 7.15-for-1 basis, after giving effect to the Company’s reverse stock split, which was effected on June 17, 2015.
Schedule of Stock Option Grants to the Company's Employees and Non-Employees	Information regarding the Company’s stock option grants to the Company’s employees and non-employees, along with the estimated fair value per share of the underlying common stock, for stock options granted since 2005 is summarized as follows: Grant Date Number of Common Shares Underlying Options Granted Exercise Price per Common Share Estimated Fair Value per Share of Common Stock Intrinsic Value Per Option 2005 58,321 $ 0.07 $ 1.79 $ 1.72 2009 60,559 $ 0.72 - $0.79 $ 4.43 $ 3.71 - $3.64 2011 33,846 $ 1.03 $ 1.00 $ 0.00 2012 60,019 $ 1.14 $ 1.14 $ 0.00 2013 100,000 $ 1.14 - $1.30 $ 1.14 $ 0.00 2014 1,626,740 $ 5.86 - $13.23 $ 5.86 $ 0.00 2015 34,000 $ 2.25 $ 2.25 $ 0.00
Summary of the Options Granted to Employees and Non-employees	The following represents a summary of the options granted to employees and non-employees outstanding at December 31, 2015 and changes during the period then ended: Options Weighted Average Exercise Price Outstanding at December 31, 2014 1,952,516 $ 7.022 Granted 34,000 2.250 Exercised/Expired/Forfeited (47,982 ) (1.246 ) Outstanding at December 31, 2015 1,938,534 $ 7.081 Exercisable at December 31, 2015 697,832 $ 5.285 Expected to be vested 1,240,702 $ 8.091
Option Pricing Method [Member]
Schedule Assumptions Used in Black-scholes Option-pricing Method	The OPM relies on the Black-Scholes option-pricing model to value the call options on the Company’s invested capital. The following inputs were applied in the Black-Scholes calculations of the OPM: Valuation Dates November 7, 2013 July 31, 2012 December 31, 2010 Risk-free rate 0.55 % 0.57 % 2.01 % Maturity (years) 3.00 4.00 5.00 Volatility 58.00 % 61.00 % 61.00 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes Tables
Schedule of Reconiliation of Statutory Income Tax Rate	A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: December 31, 2015 2014 Statutory U.S. federal rate 34.0 % 34.0 % State income tax, net of federal benefit 5.8 % 3.9 % Meals & entertainment (0.1 )% (0.3 )% Others 0.0 % (0.5 )% Forward sale of preferred stock 0.0 % (2.3 )% Non-cash interest on conversion 0.0 % (2.8 )% Valuation allowance (39.7 )% (32.0 )% Provision for income taxes 0.0 % 0.0 %
Schedule of Deferred Tax Assets	The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following: As of December 31, 2015 2014 Deferred tax assets: Net operating loss carry forwards $ 6,192,058 $ 3,675,012 Patent costs 410,913 318,652 Capitalized interest 85,568 85,568 Accrued vacation 27,852 10,237 Research and development credit 345,721 200,482 Stock-based compensation 1,480,266 383,381 Other 5,195 4,460 Gross deferred tax assets 8,547,573 4,677,792 Valuation allowance (8,547,573 ) (4,677,792 ) Net deferred tax assets $ — $ —

Organization and Principal Ac25

Organization and Principal Activities (Details Narrative) - USD ($)	Jun. 29, 2015	Jun. 29, 2015	Dec. 31, 2015	Dec. 31, 2014
Organization And Principal Activities [Line Items]
Offering expenses			$ 2,194,375
IPO [Member]
Organization And Principal Activities [Line Items]
Number of common shares sold	4,000,000	4,000,000
Shares of common stock sold, per share	$ 5	$ 5
Underwriting discounts and commissions	$ 1,600,000	$ 1,600,000
Offering expenses		1,000,000
Net offering proceeds		$ 17,400,000
Stock reverse split		1–for-7.15 reverse split

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ 8,787,771	$ 2,473,465
Net cash used in operating activities	$ 5,721,565	$ 1,157,385

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Detail Narrative)	Jun. 17, 2015	Jun. 30, 2015	Dec. 31, 2015
Accounting Policies [Abstract]
Reverse stock split, Description	1-for-7.15 reverse stock split	1-for-7.15 reverse stock split	7.15-for-1 basis
Reverse stock split, Ratio		7.15

Property and equipment (Details

Property and equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,939	$ 3,479

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 25,536	$ 9,757
Accumulated depreciation	(4,848)	(4,585)
Total property and equipment, net of accumulated depreciation	20,688	5,172
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 15,840	4,270
Estimated Life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 9,696	$ 5,487
Estimated Life	5 years

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	1 Months Ended	5 Months Ended	12 Months Ended
	Oct. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Oct. 09, 2014
Debt Disclosure [Abstract]
Convertible note payable and note payable principal balance			$ 605,000
Principal and accrued but unpaid interest			3,000,000
Convertible notes payables			535,000
Note payable term	12 months	12 months
Convertible subordinated debt	$ 80,000	$ 455,000
Percentage of bear interest rate per annum until paid in full	8.00%	8.00%		5.00%
Percentage of price per shaer paid by investors	75.00%	75.00%
Debt discount approximately		$ 21,000
Amortized interest expense			10,000
Recognized a gain approximately from notes			$ 21,000
Unsecured Debt				$ 70,000

Commitments and Contingencies31

Commitments and Contingencies (Details Narrative)	Jul. 09, 2015ft²	Dec. 02, 2014USD ($)$ / sharesshares	Sep. 25, 2013shares	Jul. 30, 2015USD ($)kg$ / kg	Jun. 29, 2015USD ($)$ / sharesshares	Apr. 30, 2013USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / shares	Jul. 31, 2015shares	Jul. 29, 2015shares	Jul. 24, 2015USD ($)$ / sharesshares	Sep. 30, 2013shares
Common shares issued, par value per share | $ / shares					$ 0.001		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Lease agreement term								2 years
Minimum monthly rent								$ 5,000
Percentage of increase in annual rent								3.00%
Rent expense								$ 74,000		$ 60,000
Excersie price per shares | $ / shares								$ 2.250
Century Park [Member]
Lease agreement term	61 months
Area of lease | ft²	2,780
Months 2 Through 13 [Member]
Rent expense								$ 9,174
Lease term description								months 2 through 13 of the term
Months 50 Through 61 [Member]
Rent expense								$ 10,325
Lease term description								months 50 through 61
Annual Excess Milestone Payments [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]
Percentage of initial target bonus opportunities of base salary									3.00%
Cash bonus									$ 1,000,000
Number of stock options expected to vest | shares							6,993	6,993	6,993
Number of stock options vested | shares									6,993
Vesting period of options									36 months
Percentage of option vest									35.00%
Initial period license payment									$ 2,000,000
Ira Ritter [Member]
Annual base salary								$ 103,250
Percentage of initial target bonus opportunities of base salary								35.00%
Ira Ritter [Member] | Executive Compensation Plan [Member]
Annual base salary					$ 295,000
Ira Ritter [Member] | 2008 Stock Plan [Member]
Options to purchase of common stock shares | shares								48,951
Andrew Ritter [Member]
Annual base salary								$ 124,000
Percentage of initial target bonus opportunities of base salary								40.00%
Andrew Ritter [Member] | Executive Compensation Plan [Member]
Annual base salary					$ 310,000
Tuition reimbursement, payable period					3 years
Maximum offer entitled to receive					$ 180,000
Paid an aggregate of tuition reimbursement								$ 105,000
Accrued tuition reimbursement							$ 75,000	$ 75,000	$ 75,000
Andrew Ritter [Member] | 2008 Stock Plan [Member]
Options to purchase of common stock shares | shares								48,951
Executive [Member] | FDA Meeting Bonus Opportunities [Member]
Cash bonus						$ 10,000
Executive [Member] | Clinical Trial Funding Commitment Bonus Opportunities [Member]
Cash bonus								$ 75,000
Number of stock options expected to vest | shares												3,671
Number of stock options vested | shares								10,489
Stock options to vest ratably on a monthly basis | shares											6,818
Vesting period of options								36 months
Minimum actual deployment of funds by third party								$ 2,000,000
Percentage of option vest								35.00%
Bonus received								$ 75,000
Executive [Member] | Fundraising Bonus Opportunities [Member]
Cash bonus								50,000
Minimum actual deployment of funds by third party								$ 2,000,000
Executive [Member] | License Event Bonus Opportunities [Member]
Percentage of initial target bonus opportunities of base salary									35.00%
Number of stock options expected to vest | shares							45,454	45,454	45,454
Number of stock options vested | shares									45,454
Vesting period of options									36 months
Minimum upfront payment of license									$ 2,000,000
Initial period license payment									$ 2,000,000
Executive [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]
Number of shares called by options | shares							48,951	48,951	48,951
Number of stock options expected to vest | shares							27,972	27,972	27,972
Percentage of initial period license payment									5.00%
Initial period license payment									$ 5,000,000
Executive [Member] | Executive Options [Member] | FDA Meeting Bonus Opportunities [Member]
Number of stock options expected to vest | shares			3,496
Number of stock options vested | shares			2,360
Stock options to vest ratably on a monthly basis | shares														1,136
Executive One [Member] | Fundraising Bonus Opportunities [Member]
Cash bonus								$ 150,000
Minimum actual deployment of funds by third party								$ 10,000,000
Executive One [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]
Percentage of initial period license payment							4.00%
Executive One [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member] | Minimum [Member]
Initial period license payment									5,000,000
Executive One [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member] | Maximum [Member]
Initial period license payment									$ 10,000,000
Executive One [Member] | Executive Options [Member] | Fundraising Bonus Opportunities [Member]
Percentage of initial target bonus opportunities of base salary							35.00%	35.00%
Number of stock options expected to vest | shares							6,993	6,993	6,993			4,895
Number of stock options vested | shares							13,986	6,993
Stock options to vest ratably on a monthly basis | shares											9,091
Vesting period of options							36 months	36 months
Bonus received								$ 150,000
Proceeds from issuance of shares upon closing of initial public offering								17,400,000
Executive Two [Member] | Fundraising Bonus Opportunities [Member]
Minimum actual deployment of funds by third party								$ 2,000,000
Executive Two [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]
Percentage of initial period license payment									3.00%
Initial period license payment									$ 10,000,000
Amended Clinical Supply And Cooperation Agreement [Member] | Ricerche Sperimentali Montale Spa And Inalco Spa [Member]
Further option payment due in future													$ 1,000,000
Number of common shares to be issued | shares							100,000	100,000	100,000				100,000
Common shares issued, par value per share | $ / shares													$ 0.001
Fair value of shares to be paid							$ 416,000	$ 416,000	$ 416,000
Amended Clinical Supply And Cooperation Agreement [Member] | Ricerche Sperimentali Montale Spa And Inalco Spa [Member] | Contractual Rights [Member]
Payment for GOS IP				$ 800,000
Payment required following FDA approval to RSM				$ 400,000
GOS kilograms | kg				350
GOS price per kilo | $ / kg				250
GOS price per kilo under existing supply agreement (in dollars per kilo) | $ / kg				2,000
Step Letter Agreement [Member] | Chief Executive Officer [Member]
Annual base salary		$ 360,000
Step Letter Agreement [Member] | Chief Executive Officer [Member] | Employee Stock Option [Member]
Number of shares called by options | shares		646,537
Excersie price per shares | $ / shares		$ 5.86
Description of right to repurchase lapse		1/44th of the total number of shares subject to the right of repurchase
Step Letter Agreement [Member] | Chief Executive Officer [Member] | Employee Stock Option Two [Member]
Number of shares called by options | shares		73,377
Excersie price per shares | $ / shares		$ 5.86
Description of right to repurchase lapse		1/44th of the total number of shares subject to the right of repurchase
Step Letter Agreement [Member] | Chief Executive Officer [Member] | Employee Stock Option Three [Member]
Number of shares called by options | shares					163,799
Percentage shares of common stock deemed to be outstanding					7.50%
Description of right to repurchase lapse					1/36th of the total number of shares subject to the right of repurchase

Commitments and Contingencies -

Commitments and Contingencies - Summarized Operating Lease Obligations (Details)	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 110,638
2,017	113,958
2,018	117,376
2,019	120,898
2,020	103,254
Total minimum lease payments	$ 566,124

Stockholders' Equity (Deficit33

Stockholders' Equity (Deficit) and Preferred Stock Subject to Redemption (Details Narrative) - USD ($)	Dec. 18, 2015	Jun. 29, 2015	Jun. 17, 2015	Mar. 26, 2015	Jun. 30, 2015	Jun. 29, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Common stock, shares authorized		25,000,000				25,000,000	50,000,000	25,000,000	50,000,000
Common stock, par value		$ 0.001				$ 0.001	$ 0.001	$ 0.001	$ 0.001
Reverse stock split description			1-for-7.15 reverse stock split		1-for-7.15 reverse stock split			7.15-for-1 basis
Underwriters paid an aggregate purchase price									$ 100
Warrant issued to purchase number of common stock									160,000
Warrants exercise price							$ 9.30	$ 8.45	$ 9.30
Number of preferred stock and preferred stock subject to redemption converted into common stock (in shares)								3,322,652
Preferred stock, shares authorized		5,000,000				5,000,000	8,887,500	5,000,000	8,887,500
Preferred stock, par value		$ 0.001				$ 0.001	$ 0.001	$ 0.001	$ 0.001
Unpaid principal plus							$ 605,000		$ 605,000
Accrued interest							$ 3,000,000		3,000,000
Payments to research and development								$ 2,260,297	$ 113,931
Aspire Capital Fund LLC [Member]
Number of common shares sold	500,000
Shares of common stock sold, per share	$ 2
Payments to acquire common stock	$ 10,000,000
Purchase agreement term	30 months
Aggregate of shares issued during period	188,864
Number of stock sold during period, value	$ 1,000,000
Kolu Pohaku Management And Kolu Pohaku Technologies [Member] | Research And Development Agreement & License [Member]
Payments to research and development								1,750,000
Kolu Pohaku Technologies [Member] | Research And Development Agreement & License [Member]
Payment to royalty								$ 32,000
Exercised period term								March 31, 2015 and continuing through December 31, 2035
Kolu Pohaku Management [Member] | Research And Development Agreement & License [Member]
Payment to royalty				$ 1,469,994
IPO [Member]
Number of common shares sold		4,000,000				4,000,000
Shares of common stock sold, per share		$ 5				$ 5
Aggregate gross proceeds from sale of common stock		$ 20,000,000
Underwriting discounts and commissions		1,600,000				$ 1,600,000
Other expenses with offering		1,000,000
Underwriters paid an aggregate purchase price		$ 100
Warrant issued to purchase number of common stock		160,000
Percentage of initial public offering shares		4.00%
Warrants exercise price		$ 6.25				$ 6.25
Warrants exercisable expiration		June 29, 2016 and expire on June 29, 2020
Percentage of warrants exercise price equal to initial public offering price		125.00%
Number of preferred stock and preferred stock subject to redemption converted into common stock (in shares)		3,322,652				3,322,652
Aggregate converted shares of the common stock upon the closing of the IPO								205,593
Series C Preferred Stock [Member]
Shares of common stock sold, per share								$ 1.30
Number of preferred stock and preferred stock subject to redemption converted into common stock (in shares)							331,358		331,358
Aggregate of shares issued during period		3,322,650					2,369,228
Preferred stock, shares authorized								4,500,000
Preferred stock, par value								$ 0.001
Preferred stock annual dividend rate per share								0.104
Preferred stock liquidation preference, per share								$ 1.30
Number of warrant to puchase an aggregate shares							331,358
Aggregate gross proceeds							$ 3,081,893
Purchase price per shares							$ 7.83		$ 7.83
Warrants discount initial carrying value per share							$ 1.47
Unpaid principal plus							$ 535,000	$ 535,000	$ 535,000
Accrued interest								$ 18,342
Number of shares converted into shares of preferred stock							567,529	79,374
Number of warrant issued during period								79,374
Percentage of warants to purchase share of common stock								75.00%
Number of debt conversion								$ 184,445
Outstanding debt and accrued interest							100.00%		100.00%
Series C Preferred Stock [Member] | Warrant [Member]
Unpaid principal plus								70,000
Series C Preferred Stock [Member] | Conversion One [Member]
Unpaid principal plus								70,000
Accrued interest								$ 537
Number of shares converted into shares of preferred stock								7,589	54,259
Number of warrant issued during period								7,589
Series A-1 Preferred Stock Member
Shares of common stock sold, per share								$ 0.07
Preferred stock, shares authorized								7,200,000
Preferred stock, par value								$ 0.001
Preferred stock annual dividend rate per share								0.00556
Preferred stock liquidation preference, per share								1.19
Original issue price per share, per share								0.07
Series A-2 Preferred Stock [Member]
Shares of common stock sold, per share								$ 0.40
Preferred stock, shares authorized								1,687,500
Preferred stock, par value								$ 0.001
Preferred stock annual dividend rate per share								0.032
Preferred stock liquidation preference, per share								1.19
Original issue price per share, per share								0.40
Series A-3 Preferred Stock [Member]
Shares of common stock sold, per share								$ 0.62
Preferred stock, shares authorized								4,220,464
Preferred stock, par value								$ 0.001
Preferred stock annual dividend rate per share								0.04957
Preferred stock liquidation preference, per share								0.62
Original issue price per share, per share								0.62
Series B Preferred Stock [Member]
Shares of common stock sold, per share								$ 1.19
Preferred stock, shares authorized								7,658,182
Preferred stock, par value								$ 0.001
Preferred stock annual dividend rate per share								0.09524
Preferred stock liquidation preference, per share								1.19
Preferred stock undeclared divivdends in arrears		$ 2,000,000							$ 1,700,000
Original issue price per share, per share								1.19
Series B Preferred Stock [Member] | Kolu Pohaku Technologies [Member] | Option Agreement [Member]
Original issue price per share, per share								$ 1.19
Payments to research and development								$ 1,750,000
Shares issued								1,469,994

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Warrants exercise price per share	$ 9.30	$ 8.45
Underwriters paid an aggregate purchase price	$ 100
Warrant issued to purchase number of common stock	160,000
Common stock exercise price	$ 6.25
Investor [Member]
Warrants term	7 years
Issuance of warrants to purchase of common stock shares	418,321
Warrants exercise price per share	$ 9.30

Warrants - Summary of Warrants

Warrants - Summary of Warrants Activity (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Warrants - Summary Of Warrants Activity Details
Warrants, Outstanding Beginning Balance | shares	418,323
Warrants, Granted | shares	160,000
Warrants, Exercised/Expired/ Forfeited | shares
Warrants, Outstanding Ending Balance | shares	578,323
Warrants, Exercisable | shares	418,323
Weighted Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 9.30
Weighted Average Exercise Price, Granted | $ / shares	$ 6.25
Weighted Average Exercise Price, Exercised/Expired/ Forfeited | $ / shares
Weighted Average Exercise Price, Outstanding Ending Balance | $ / shares	$ 8.45
Weighted Average Exercise Price, Exercisable | $ / shares	$ 9.30

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	Jun. 17, 2015	Oct. 31, 2014	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2011	Dec. 31, 2015	Dec. 31, 2014	Nov. 07, 2013	Jul. 31, 2012	Dec. 31, 2010
Number of options granted						34,000
Excersie price per shares						$ 2.250
Number of options outstanding				1,952,516		1,938,534	1,952,516
Stock based compensation expense						$ 2,894,509	$ 707,390
Exercise price of outstanding options				$ 7.022		$ 7.081	$ 7.022
Reverse stock split description	1-for-7.15 reverse stock split		1-for-7.15 reverse stock split			7.15-for-1 basis
Market value of invested capital total		$ 25,200,000						$ 15,500,000	$ 14,400,000	$ 8,900,000
Common stock value		$ 1,400,000		$ 465		$ 8,582	$ 465	$ 819,000	$ 870,000	$ 670,000
Common stock discount rate		21.40%
Fair value of common stock price per share		$ 5.86						$ 1.17	$ 1.19	$ 1.03
Percentage of initial public offering				45.00%			45.00%
Percentage for other scenarios				55.00%			55.00%
Series A-1 Preferred Stock Member
Additional capital through sales of preferred shares						$ 0.07
Series A-2 Preferred Stock [Member]
Additional capital through sales of preferred shares						0.40
Series A-3 Preferred Stock [Member]
Additional capital through sales of preferred shares						0.62
Series B Preferred Stock [Member]
Additional capital through sales of preferred shares						1.19
Series C Preferred Stock [Member]
Additional capital through sales of preferred shares						$ 1.30
Minimum [Member]
Common stock discount rate						35.80%
Fair value of common stock price per share				$ 1.14		$ 1.70	$ 1.14
Maximum [Member]
Common stock discount rate						40.00%
Fair value of common stock price per share				$ 5.86		$ 5.86	$ 5.86
Employee Stock Option [Member]
Weighted average period of compensation cost expected to be recognized						1 year 6 months
Employee Stock Option [Member] | Consultants [Member]
Number of options granted						7,272
Term of employee share base compensation						36 months
Percentage of vesting percentage of option					25.00%	25.00%
Exercise price of outstanding options					$ 1
Number of option purchase an aggregate shares granted					7,271	7,271
Employee Stock Option [Member] | Minimum [Member] | Consultants [Member]
Exercise price of outstanding options						$ 0.72
Employee Stock Option [Member] | Maximum [Member] | Consultants [Member]
Exercise price of outstanding options						$ 2.25
Employee Stock Option [Member] | Executive Directors And Employees [Member]
Aggregate number of shares of common stock authorized to issue						30,000
Vesting period of options						10 years
Number of options granted						41,957	1,996,712
Term of employee share base compensation							10 years
Number of options expired or exercised				82,107
Aggregate option issued to related party				1,914,605		1,902,648
Unrecognized compensation cost related to un-vested stockbased compensation						$ 2,100,000
Employee Stock Option [Member] | Executive Directors And Employees [Member] | General and Administrative Expense [Member]
Stock based compensation expense						$ 2,900,000	$ 700,000
Employee Stock Option [Member] | Executive Directors And Employees [Member] | Minimum [Member]
Excersie price per shares						$ 0.79	$ 0.79
Employee Stock Option [Member] | Executive Directors And Employees [Member] | Maximum [Member]
Excersie price per shares						$ 13.23	$ 13.23
Employee Stock Option [Member] | Non Employee Director [Member]
Aggregate number of shares of common stock authorized to issue				106,573		4,000	106,573
Vesting period of options						10 years
Number of options expired or exercised						6,025	68,662
Number of options outstanding				37,911		35,886	37,911
Stock based compensation expense						$ 1,300	$ 13,000
Stock Plan 2015 [Member] | Employee Stock Option [Member]
Aggregate number of shares of common stock authorized to issue						172,448
Stock option description						The exercise price for an option issued under the Plans is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors but shall not exceed a ten-year period.
Vesting period of options						10 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule Assumptions Used in Black-Scholes Option-Pricing Method (Details) - $ / shares	Nov. 07, 2013	Jul. 31, 2012	Dec. 31, 2010	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2014
Expected dividend yield				0.00%	0.00%
Expected stock-price volatility	58.00%	61.00%	61.00%
Expected stock-price volatility, Minimum				51.45%	51.45%
Expected stock-price volatility, Maximum				67.08%	64.24%
Risk-free interest rate	0.55%	0.57%	2.01%
Risk-free interest rate, Minimum				0.77%	0.88%
Risk-free interest rate, Maximum				2.27%	3.04%
Expected term of options	3 years	4 years	5 years	10 years
Stock price	$ 1.17	$ 1.19	$ 1.03			$ 5.86
Minimum [Member]
Expected term of options					5 years
Stock price				$ 1.70	$ 1.14
Maximum [Member]
Expected term of options					10 years
Stock price				$ 5.86	$ 5.86

Stock-Based Compensation - Sc38

Stock-Based Compensation - Schedule of Price Received from Sales to Third Parties of Common Stock (Details)	Dec. 31, 2015$ / shares
Series A-2 Preferred Stock [Member]
Stock issued price per share	$ 0.40
Series A-3 Preferred Stock [Member]
Stock issued price per share	0.62
Series B Preferred Stock [Member]
Stock issued price per share	1.19
2006 [Member] | Series A-2 Preferred Stock [Member]
Stock issued price per share	0.40	[1],[2]
2008-2009 [Member] | Series A-3 Preferred Stock [Member]
Stock issued price per share	0.62	[2]
2010-2013 [Member] | Series B Preferred Stock [Member]
Stock issued price per share	1.19	[2]
2014 [Member] | Series C Preferred Stock [Member]
Stock issued price per share	1.30	[2]
Common Stock [Member] | 2005 [Member]
Stock issued price per share	$ 1.79	[1]
[1]	After giving effect to the Company's conversion from an LLC to a corporation
[2]	Each share of preferred stock is convertible into shares of the Company's common stock on a 7.15-for-1 basis, after giving effect to the Company's reverse stock split, which was effected on June 17, 2015.

Stock-Based Compensation - Sc39

Stock-Based Compensation - Schedule of Stock Option Grants to the Company's Employees and Non-Employees (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	34,000
Exercise Price per Common Share	$ 2.250
2005 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	58,321
Exercise Price per Common Share	$ 0.07
Estimated Fair Value per Share of Common Stock	1.79
Intrinsic Value Option	$ 1.72
2009 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	60,559
Estimated Fair Value per Share of Common Stock	$ 4.43
2009 [Member] | Minimum [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Exercise Price per Common Share	0.72
Intrinsic Value Option	3.71
2009 [Member] | Maximum [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Exercise Price per Common Share	0.79
Intrinsic Value Option	$ 3.64
2011 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	33,846
Exercise Price per Common Share	$ 1.03
Estimated Fair Value per Share of Common Stock	1
Intrinsic Value Option	$ 0
2012 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	60,019
Exercise Price per Common Share	$ 1.14
Estimated Fair Value per Share of Common Stock	1.14
Intrinsic Value Option	$ 0
2013 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	100,000
Estimated Fair Value per Share of Common Stock	$ 1.14
Intrinsic Value Option	0
2013 [Member] | Minimum [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Exercise Price per Common Share	1.14
2013 [Member] | Maximum [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Exercise Price per Common Share	$ 1.30
2014 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	1,626,740
Estimated Fair Value per Share of Common Stock	$ 5.86
Intrinsic Value Option	0
2014 [Member] | Minimum [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Exercise Price per Common Share	5.86
2014 [Member] | Maximum [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Exercise Price per Common Share	$ 13.23
2015 [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Number of Common Shares Underlying Options Granted | shares	34,000
Exercise Price per Common Share	$ 2.25
Estimated Fair Value per Share of Common Stock	2.25
Intrinsic Value Option	$ 0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of the Options Granted to Employees and Non-Employees (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Outstanding, begining | shares	1,952,516
Number of Options, Granted | shares	34,000
Number of Options, Exercised/ Expired/ Forfeited | shares	(47,982)
Number of Options, Outstanding at ending | shares	1,938,534
Number of Options, Exercisable | shares	697,832
Number of Options, Expected to be vested | shares	1,240,702
Weighted Average Exercise Price, Outstanding, begining | $ / shares	$ 7.022
Weighted Average Exercise Price, Granted | $ / shares	2.250
Weighted Average Exercise Price, Exercised/ Expired/ Forfeited | $ / shares	(1.246)
Weighted Average Exercise Price, Outstanding at ending | $ / shares	7.081
Weighted Average Exercise Price, Exercisable | $ / shares	5.285
Weighted Average Exercise Price, Expected to be vested | $ / shares	$ 8.091

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Mr. Ira Ritter [Member] | Andela Group Inc [Member] | General and Administrative Expense [Member]
Related party transaction expense		$ 176,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 15,300,000
Operating loss carryforwards expire year	2,028
Research and development credit carryforwards	$ 488,000
Research and development credit carryforwards expire year	2,028
Accruals for income tax accounting uncertainties
Interest or penalties
Unrecognized tax benefits decrease or increase during period

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconiliation of Statutory Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Statutory U.S. federal rate	34.00%	34.00%
State income tax, net of federal benefit	5.80%	3.90%
Meals & entertainment	(0.10%)	(0.30%)
Others	0.00%	(0.50%)
Forward sale of preferred stock	0.00%	(2.30%)
Non-cash interest on conversion	0.00%	(2.80%)
Valuation allowance	(39.70%)	(32.00%)
Provision for income taxes	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 6,192,058	$ 3,675,012
Patent costs	410,913	318,652
Capitalized interest	85,568	85,568
Accrued vacation	27,852	10,237
Research and development credit	345,721	200,482
Stock based compensation	1,480,266	383,381
Other	5,195	4,460
Gross deferred tax assets	8,547,573	4,677,792
Valuation allowance	$ (8,547,573)	$ (4,677,792)
Net deferred tax assets